3.68  0.21 (6.05%)		12-04 16:00
Open: 3.43 High: 3.745 Volume: 1,004,141		Pre. Close: 3.47 Low: 3.36 Market Cap: 315(M)

Short term
Mid term
Targets	6-month :	4.58	1-year :	5.16
Resists	First :	3.92	Second :	4.42
Pivot price	3.48
Supports	First :	3.11	Second :	2.59
MAs	MA(5) :	3.47	MA(20) :	3.48
	MA(100) :	3.86	MA(250) :	0
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	45.2	D(3) :	40
RSI	RSI(14): 51.2
52-week	High :	5.36	Low :	1.61

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LRMR ] has closed below upper band by 16.1%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.75 - 3.76	3.76 - 3.77
Low:	3.33 - 3.34	3.34 - 3.35
Close:	3.65 - 3.68	3.68 - 3.7

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Wed, 03 Dec 2025
Top 3 Health Care Stocks That May Rocket Higher In December - Sahm

Sun, 30 Nov 2025
Bronstein, Gewirtz & Grossman, LLC Encourages Larimar Therapeutic - The National Law Review

Fri, 28 Nov 2025
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Fri, 14 Nov 2025
Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Mon, 10 Nov 2025
Larimar Therapeutics, Inc. Updates on Nomlabofusp Development - TradingView

Wed, 05 Nov 2025
Larimar Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	86 (M)
Shares Float	37 (M)
Held by Insiders	1 (%)
Held by Institutions	100.1 (%)
Shares Short	10,080 (K)
Shares Short P.Month	8,820 (K)

EPS	-1.97
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.62
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-43 %
Return on Equity (ttm)	-78.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.63
Qtrly Earnings Growth	0 %
Operating Cash Flow	-96 (M)
Levered Free Cash Flow	-49 (M)

PE Ratio	-1.88
PEG Ratio	0
Price to Book value	2.27
Price to Sales	0
Price to Cash Flow	-3.27

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.